Use of a lysophosphatidylcholine in promoting early development of a reconstituted embryo and method
By adding lysophosphatidylcholine to the reconstructed embryo culture system, the adaptability and competitiveness of donor stem cells were enhanced, solving the problem of low reconstructed embryo development efficiency and achieving a significant increase in blastocyst development rate, laying the foundation for technological advancements in the field of embryo engineering.
Patent Information
- Application Number
- CN202610547401.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-23
- Publication Date
- 2026-07-03
AI Technical Summary
The low efficiency and developmental fidelity of reconstructed embryos are mainly due to insufficient competitiveness, proliferation capacity and survival rate of donor stem cells in the microenvironment of newborn embryos, leading to developmental arrest or structural abnormalities.
Adding lysophosphatidylcholine (LPC) at a concentration of 5 μM to the culture system of reconstructed embryos promotes the adaptability and competitiveness of donor stem cells, enhancing cell survival and proliferation by affecting cell membrane fluidity and activating intracellular signaling pathways.
It significantly improved the blastocyst development rate of reconstructed embryos to 24.56%, providing operable biochemical intervention targets for the construction of reconstructed embryos, ensuring the controllability and reproducibility of the technical solution, and supporting high-quality developmental biology research and disease model construction.
Smart Images

Figure CN122326516A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of embryo engineering technology, and in particular to the application and method of lysophosphatidylcholine in promoting early development of reconstructed embryos. Background Technology
[0002] Currently, the construction of embryonic models based on pluripotent stem cells is a cutting-edge research area at the intersection of regenerative medicine and developmental biology. Reconstructing embryos, which utilizes different types of stem cells to form blastocyst-like structures through in vitro assembly and induction, aims to mimic the morphogenesis and developmental potential of natural blastocysts, providing an irreplaceable in vitro research system for studying early embryonic development, organogenesis, and disease modeling. The standardized process of this technology typically encompasses three key steps: preparation and aggregation of starting cells, precise microinjection or assembly operations, and an optimized culture system to support its three-dimensional development. Since the landmark study in 2021 confirmed the feasibility of this technology in mouse, non-human primate, and even human stem cell systems, various technical approaches have been successfully developed, such as relying on the spontaneous differentiation of embryonic stem cells to form embryomorphic bodies, or co-culturing and physically assembling trophoblast stem cells with extended pluripotency stem cells. These breakthroughs mark a crucial step forward in reconstructing the initial blueprint of life in vitro.
[0003] Despite rapid technological advancements, the efficiency and developmental fidelity of reconstructed embryos still face significant challenges, one fundamental bottleneck being the "environmental adaptation dilemma" of donor stem cells. When donor cells (such as pluripotent stem cells) are removed from their optimal two-dimensional culture environment and placed into the highly complex and dynamically changing three-dimensional microenvironment of the reconstructed embryo, they often exhibit significant maladaptation. Compared to cells derived from the host's intracellular cell mass, these exogenous donor cells are at a disadvantage in terms of intercellular competition, proliferative activity, and directed differentiation. They struggle to effectively integrate into the embryonic developmental process, their cell cycle is prone to arrest, and they often tend towards apoptosis, leading to developmental arrest or structural abnormalities in the reconstructed embryo. Therefore, improving the competitiveness, proliferative capacity, and survival rate of donor cells in the neonatal embryonic microenvironment has become a core scientific issue for overcoming current technological bottlenecks and improving the blastocyst development rate of reconstructed embryos. To solve this problem, identifying key small molecule signals that can regulate cell fate and enhance cell adaptability has become an important strategy.
[0004] Lysophosphatidylcholine (LPC), as a phospholipid metabolite with important biological activity, exhibits unique research value in this context. LPC is a hydrolysis product of phosphatidylcholine, a major component of the cell membrane, under the action of phospholipase A2. Its molecular structure contains only one hydrophobic fatty acid chain and one hydrophilic choline head. This unique amphiphilicity gives it stronger hydrophilicity and interfacial activity than ordinary phospholipids, making it suitable as a biomembrane modifier and signaling molecule. In physiological and pathological processes, LPC acts as an important lipid second messenger, widely participating in the regulation of cell proliferation, migration, differentiation, and survival. For example, clear research evidence shows that LPC can effectively promote the proliferation of B lymphocytes and, under specific circumstances, influence the fate and differentiation direction of stem cells. These characteristics suggest that LPC may potentially enhance the adaptability and competitiveness of donor cells in unfamiliar microenvironments by influencing cell membrane fluidity and activating intracellular signaling pathways (such as G protein-coupled receptor-mediated pathways).
[0005] However, the mechanisms and functions of LPCs in the specific and intricate developmental context of embryonic reconstruction remain largely unknown. Their impact on donor stem cell survival, proliferation, and intercellular communication within the early embryonic three-dimensional assembly has never been systematically studied. Summary of the Invention
[0006] The purpose of this invention is to provide an application and method of lysophosphatidylcholine in promoting early development of reconstructed embryos. It reveals for the first time the positive function of LPC in the development of reconstructed embryos and significantly improves the construction efficiency of reconstructed embryos, which is of great significance for promoting technological progress in the field of embryo engineering.
[0007] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides the application of lysophosphatidylcholine in promoting early development of reconstructed embryos.
[0008] The present invention also provides a method for promoting early development of a reconstructed embryo, comprising the following steps: (1) Collect mature oocytes and culture them to the 8-cell stage and blastocyst stage, respectively; (2) Isolate and collect individual stem cells from the inner cell mass of the blastocyst; (3) Take an 8-cell stage embryo and fuse it with the single stem cell separated in step (2) to obtain a reconstructed embryo; (4) The reconstructed embryos were cultured in a medium containing lysophosphatidylcholine.
[0009] Preferably, in step (1), the mature oocyte is a mature oocyte with a first polar body.
[0010] Preferably, in step (3), the fusion parameters include: electric field strength of 100~120 V / mm, pulse time of 20~40 μs, and pulse number of 1~3 DC.
[0011] Preferably, in step (5), the concentration of lysophosphatidylcholine in the culture medium is 1~7 μM.
[0012] The beneficial effects of this invention compared to the prior art are as follows: This invention provides a method for promoting early development of reconstructed embryos. First, reconstructed embryos are prepared, and then lysophosphatidylcholine (LPC) is added to the culture system for further culture. Lysophosphatidylcholine effectively promotes early development of reconstructed embryos; at an optimal concentration of 5 μM, the blastocyst development rate increases to 24.56%. This provides a novel and operable biochemical intervention target for solving the problem of low reconstructed embryo culture efficiency. This invention not only fills the gap in our understanding of the mechanism of action of LPC in this field, but more importantly, by precisely defining the optimal concentration window (5 μM), it achieves controllability and reproducibility of the technical solution. It provides key parameters for establishing standardized culture procedures and lays a more solid foundation for downstream applications such as developmental biology research and disease model construction that rely on high-quality reconstructed embryos, significantly accelerating the process of related scientific discovery and application development. Attached Figure Description
[0013] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0014] Figure 1 This is a schematic diagram of the reconstructed embryo preparation process in an embodiment of the present invention.
[0015] Figure 2 This is a schematic diagram of a blastocyst in an embodiment of the present invention. Detailed Implementation
[0016] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0017] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0018] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.
[0019] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This specification and embodiments are merely exemplary.
[0020] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.
[0021] This invention provides a method for promoting early development of a reconstructed embryo, comprising the following steps: (1) Collect mature oocytes and culture them to the 8-cell stage and blastocyst stage respectively; among them, the mature oocytes are mature oocytes with the first polar body.
[0022] (2) Isolate and collect single stem cells from the inner cell mass of the blastocyst; wherein the fusion parameters include: electric field strength 100~120 V / mm, pulse time 20~40 μs, pulse number 1~3 DC; more preferably, electric field strength 110 V / mm, pulse time 30 μs, pulse number 2 DC.
[0023] (3) Take an 8-cell stage embryo and fuse it with the single stem cell separated in step (2) to obtain a reconstructed embryo; (4) The reconstructed embryos are cultured in a culture medium containing lysophosphatidylcholine; wherein the concentration of lysophosphatidylcholine in the culture medium is 1~7 μM, more preferably 5 μM.
[0024] Example 1 (1) Obtaining mature mouse oocytes Female Kunming mice aged 6-10 weeks (Wuhan CDC) were kept under controlled light conditions of 14 hours of light and 10 hours of darkness for 1-2 weeks. Then, they were injected intraperitoneally with 10 IU / vial PMSG (Ningbo Hormone Products Factory) for 46-48 hours, followed by intraperitoneal injection of 10 IU / vial hCG (Ningbo Hormone Products Factory) to induce superovulation.
[0025] 20-22 hours after superovulation, the superovulated mice were euthanized by cervical dislocation. The ampulla was dissected to obtain superovulated oocytes. These oocytes were observed under an inverted microscope, and mature oocytes with the first polar body were collected. After washing three times in M2 medium, they were cultured in embryo culture medium M16 to the 8-cell and blastocyst stages for later use. Culture conditions: 37℃, 5% CO2, saturated humidity.
[0026] (2) Isolate and collect individual stem cells from the inner cell mass of the blastocyst. In step (1), the blastocysts were treated with 0.25% streptomycin to remove the zona pellucida. The inner cell mass was digested with 0.25% commercial trypsin. The cells were gently pipetted using a 20-200 μL pipette to separate and collect individual stem cells from the inner cell mass of the blastocyst. These cells were then transferred to manifold droplets containing M2 for later use. Manifold droplet preparation: Using a 10-100 μL pipette, 15 μL of M2 was pipetted onto a Φ35 mm disposable dish. Each droplet was 15 μL in size and covered with paraffin oil for later use.
[0027] (3) Preparation of reconstructed embryos Using a fixation needle with an inner diameter of 10 μm and an outer diameter of 90 μm, fix the 8-cell stage embryo from the 9 o'clock position. Using an injection needle with an inner diameter of 10-15 μm, aspirate one blastomer and insert it from the 3 o'clock position. Using the Piezo system, rupture the zona pellucida and inject the embryo into the pore beneath the zona pellucida. Gently press with the injection needle to ensure the stem cells and 8-cell cluster are in as close contact as possible before use. Figure 1 (As shown). Piezo injection parameters: zona pellucida 3, cell membrane 1.
[0028] (4) Reconstructed embryo fusion Cell fusion was performed using a BTX-2001 fusion apparatus. Fusion solution was added to the fusion tank, the apparatus was connected, and embryos after stem cell transplantation were harvested. The embryos were washed three times each in DPBS and fusion solution before being transferred into the fusion tank, ensuring the newly injected stem cells and 8-cell stage cell clusters were perpendicular to the positive and negative electrodes. Fusion parameters: 110V / mm, 30 μs, 2DC. The reconstructed embryos were placed in M16 cells and observed for 3 days, with blastocyst development rates recorded. Culture conditions: 37℃, 5% CO2, saturated humidity. Fusion solution formulation: 0.25 mmol / L mannitol + 0.5 mmol / L calcium chloride + 0.5 mmol / L sulfuric acid + 0.5 mol / L HEPES + 0.01% PVA.
[0029] (5) Treatment with lysophosphatidylcholine The reconstructed embryos prepared in step (4) were placed in M16 medium containing 0 μM, 5 μM, 10 μM, 15 μM, and 20 μM lysophosphatidylcholine, respectively, with a blank control group included. After 3 days of continuous culture, the blastocysts were observed and counted. Figure 2 The development rate was compared with the effect of lysophosphatidylcholine on the development of reconstructed embryos. Culture conditions: 37℃, 5% CO2, saturated humidity. Results are shown in Table 1.
[0030] Table 1. Effects of lysophosphatidylcholine on the development of reconstructed mouse embryos.
[0031] Table 1 shows that the addition of lysophosphatidylcholine to M16 can promote the development of reconstructed embryos and increase the blastocyst rate, with 5 μM lysophosphatidylcholine showing the most significant effect.
[0032] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. The application of a lysophosphatidylcholine in promoting early development of reconstructed embryos.
2. A method for promoting early development of a reconstructed embryo, characterized in that, Includes the following steps: (1) Collect mature oocytes and culture them to the 8-cell stage and blastocyst stage, respectively; (2) Isolate and collect individual stem cells from the inner cell mass of the blastocyst; (3) Take an 8-cell stage embryo and fuse it with the single stem cell separated in step (2) to obtain a reconstructed embryo; (4) The reconstructed embryos were cultured in a medium containing lysophosphatidylcholine.
3. The method for promoting early embryonic development according to claim 2, characterized in that, In step (1), the mature oocyte is a mature oocyte with a first polar body.
4. The method for promoting early development of a reconstructed embryo according to claim 2, characterized in that, In step (3), the fusion parameters include: electric field strength 100~120 V / mm, pulse time 20~40 μs, and pulse number 1~3 DC.
5. The method for promoting early development of a reconstructed embryo according to claim 2, characterized in that, In step (5), the concentration of lysophosphatidylcholine in the culture medium is 1~7 μM.
